Antigenics AGEN Phase 3 Trial QS-21 - 6/17/09

Antigenics Inc. (AGEN) stock is ripping higher in pre market today, 6/17/09. Shares of AGEN are trading at $2.25 Up 16% due to the following news. Discuss AGEN

Discuss Stocks: http://stockstobuy.org

Antigenics' QS-21 Adjuvant Enters Pivotal Phase 3 Clinical Trial of GlaxoSmithKline's Malaria Vaccine

June 17, 2009 - Antigenics Inc. (NASDAQ: AGEN) today announced that GlaxoSmithKline (GSK) has launched a Phase 3 study with the world’s most clinically-advanced malaria vaccine, RTS,S, which contains Antigenics’ QS-21 Stimulon® adjuvant

“There are now approximately 15 vaccines containing QS-21 in clinical trials of which four have now progressed into Phase 3 studies across multiple indications including non-small cell lung cancer, melanoma and malaria,” said Garo H. Armen, PhD, chairman and CEO of Antigenics. “Today’s announcement demonstrates that QS-21 is a critical adjuvant in the development of therapeutic and prophylactic vaccines and is expected to be a significant contributor to Antigenics future royalty income in the event of successful commercialization.”

QS-21 is a key component in several of GSK’s proprietary adjuvant systems, which play an integral role in a new generation of GSK vaccines currently in development. Under the terms of the license and supply agreements announced in July 2006, GSK will make payments contingent upon successful milestone achievements, and will pay royalties to Antigenics on net sales for a period of at least 10 years after first commercial sale.

Full Article

For the latest updates on the stock market, visit, http://daytradingstockblog.blogspot.com/ or Subscribe for Free